Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium Tc 99m hydrazinonicotinamide-tricine-linked interleukin-2
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
99mTc-HYNIC-IL2 is an investigational radiopharmaceutical imaging agent developed by the Mayo Clinic for the non-invasive visualization of tumor-infiltrating lymphocytes (TILs). The agent consists of recombinant human interleukin-2 (IL-2) conjugated with hydrazinonicotinamide (HYNIC) and labeled with the radionuclide technetium-99m (99mTc), utilizing tricine as a coligand. It specifically targets the IL-2 receptor (CD25) expressed on activated T lymphocytes. In clinical pilot studies, 99mTc-HYNIC-IL2 scintigraphy is being evaluated in patients with stage IV metastatic melanoma undergoing immunotherapy with checkpoint inhibitors (such as ipilimumab or pembrolizumab). The primary goal is to differentiate between true tumor progression and inflammatory pseudoprogression by assessing the presence and changes in TIL density within metastatic lesions.
- Other names
- technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-299mTc-labeled interleukin-2technetium Tc 99m HYNIC-IL2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on technetium Tc 99m hydrazinonicotinamide-tricine-linked interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium Tc 99m hydrazinonicotinamide-tricine-linked interleukin-2.